{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:21:28Z","timestamp":1772738488724,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1984,7,1]],"date-time":"1984-07-01T00:00:00Z","timestamp":457488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[1984,7]]},"DOI":"10.1007\/bf00313684","type":"journal-article","created":{"date-parts":[[2004,10,10]],"date-time":"2004-10-10T17:28:18Z","timestamp":1097429298000},"page":"148-152","source":"Crossref","is-referenced-by-count":13,"title":["Pergolide therapy in parkinson's disease"],"prefix":"10.1007","volume":"231","author":[{"given":"P.","family":"Jeanty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"van den Kerchove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lowenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00002826-198200051-00004","volume":"5","author":"RC Duvoisin","year":"1982","unstructured":"Duvoisin RC (1982) Management of patients who fail to respond to levodopa therapy. Clin Neuropharmacol 5:113?118","journal-title":"Clin Neuropharmacol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1212\/WNL.24.5.431","volume":"24","author":"S Fahn","year":"1974","unstructured":"Fahn S (1974) ?On-off? phenomenon with levodopa therapy in parkinsonism. Neurology (Minneap) 24:431?441","journal-title":"Neurology"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0022-510X(71)90178-X","volume":"13","author":"S Fahn","year":"1971","unstructured":"Fahn S, Libsch LR, Cutler RW (1971) Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea and tremor. J Neurol Sci 13:427?455","journal-title":"J Neurol Sci"},{"key":"CR4","first-page":"236","volume-title":"Advances in parkinsonism","author":"M Goldstein","year":"1976","unstructured":"Goldstein M (1976) Pre- and postsynaptic effects of dopaminergic agonists: anti-parkinsonian efficacity and effects of dopaminergic agonists: anti-parkinsonian efficacity and effects on dopamine synthesis: In: Birkmayer M, Hornykiewicz O (eds) Advances in parkinsonism. Roche, Basle, pp 236?243"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1073\/pnas.77.6.3725","volume":"77","author":"M Goldstein","year":"1980","unstructured":"Goldstein M, Lieberman A, Lew JY, Asano T, Rosenfeld MR, Makman MH (1980) Interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci USA 77:3725?3728","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0024-3205(74)90306-3","volume":"14","author":"O Hornykiewicz","year":"1974","unstructured":"Hornykiewicz O (1974) The mechanisms of action of L-dopa in Parkinson's disease. Life Sci 14:1249?1259","journal-title":"Life Sci"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(73)92595-6","volume":"II","author":"KR Hunter","year":"1973","unstructured":"Hunter KR, Shaw KM, Laurence DR, Stern GM (1973) Sustained levodopa therapy in parkinsonism. Lancet II:929?931","journal-title":"Lancet"},{"issue":"1","key":"CR8","first-page":"19","volume":"5","author":"J Jancovik","year":"1982","unstructured":"Jancovik J (1982) Management of motor side effects of chronic levodopa therapy. Clin Neuropharmacol 5 [Suppl 1]:19?28","journal-title":"Clin Neuropharmacol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ana.410120305","volume":"12","author":"AE Lang","year":"1982","unstructured":"Lang AE, Quinn N, Brincat S, Marsden CD, Parkes JD (1982) Pergolide in late-state Parkinson disease. Ann Neurol 12:243?247","journal-title":"Ann Neurol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1212\/WNL.22.5_Part_2.3","volume":"22","author":"HM Langrall","year":"1972","unstructured":"Langrall HM, Joseph C (1972) Evaluation of safety and efficacity of levodopa in Parkinson's disease and syndrome. Neurology (Minneap) 22 [Suppl]:3?16","journal-title":"Neurology"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(81)90956-9","volume":"II","author":"AJ Lees","year":"1981","unstructured":"Lees AJ, Stern GM (1981) Pergolide and lisuride for levodopa-induced oscillations. (Letter) Lancet II:577","journal-title":"Lancet"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.382359","volume":"205","author":"L Lemberger","year":"1979","unstructured":"Lemberger L, Crabtree RE (1979) Pharmacologic effects in man of a potent long-acting dopamine receptor agonist. Science 205:1151?1153","journal-title":"Science"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.1980.91","volume":"27","author":"L Lemberger","year":"1980","unstructured":"Lemberger L, Crabtree R, Callaghan JT (1980) Pergolide, a potent long-acting dopamine-receptor agonist. Clin Pharmacol Ther 27:642?651","journal-title":"Clin Pharmacol Ther"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.31.6.675","volume":"31","author":"A Lieberman","year":"1981","unstructured":"Lieberman A, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Kleinberg D (1981) Treatment of advanced Parkinson disease with pergolide. Neurology (NY) 31:675?682","journal-title":"Neurology"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1212\/WNL.32.10.1181","volume":"32","author":"A Lieberman","year":"1982","unstructured":"Lieberman A, Goldstein M, Gopinathan G, Leibowitz M, Neophytides A, Walker R, Hiesinger E, Nelson J (1982) Further studies with pergolide in Parkinson disease. Neurology (NY) 32:1181?1184","journal-title":"Neurology"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/clpt.1982.128","volume":"32","author":"A Lieberman","year":"1982","unstructured":"Lieberman A, Goldstein M, Neophytides A, Leibowitz M, Gopinathan G, Walker R, Pact V (1982) The use of pergolide, a potent dopamine agonist in Parkinson's disease. Clin Pharmacol Ther 32:70?75","journal-title":"Clin Pharmacol Ther"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(76)91416-1","volume":"I","author":"CD Marsden","year":"1976","unstructured":"Marsden CD, Parkes JD (1976) ?On-off? effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet I:292?296","journal-title":"Lancet"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/brain\/88.1.181","volume":"88","author":"LJ Poirier","year":"1965","unstructured":"Poirier LJ, Sourkes TL (1965) Influence of the substantia nigra on the catecholamine content of the striatum. Brain 88:181?192","journal-title":"Brain"},{"key":"CR19","first-page":"149","volume-title":"Research progress in Parkinson's disease. Progress in neurology series","author":"P Riederer","year":"1981","unstructured":"Riederer P, Teynolds G, Birkmayer W (1981) Neurochemical correlates of symptomatology and drug induced side effects in Parkinson's disease. In: Rose FC, Capildeo R (eds) Research progress in Parkinson's disease. Progress in neurology series. Pitman Books Ltd, London, pp 149?157"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/clpt.1981.157","volume":"30","author":"A Rubin","year":"1981","unstructured":"Rubin A, Lemberger L, Dhahir P (1981) Physiologic disposition of pergolide. Clin Pharmacol Ther 30:258?265","journal-title":"Clin Pharmacol Ther"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1212\/WNL.32.10.1175","volume":"32","author":"CM Tanner","year":"1982","unstructured":"Tanner CM, Goetz CG, Glantz RH, Glatt SL, Klawans HL (1982) Pergolide mesylate and idiopathic Parkinson disease. Neurology (NY) 32:1175?1179","journal-title":"Neurology"},{"key":"CR22","unstructured":"Webster DD (1968) Critical analysis of the disability in Parkinson's disease. Mod Treat 257?282"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00313684.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00313684\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00313684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T19:08:08Z","timestamp":1554318488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00313684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1984,7]]}},"alternative-id":["BF00313684"],"URL":"https:\/\/doi.org\/10.1007\/bf00313684","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,7]]}}}